bispecific antibodies

Showing 1 posts of 1 posts found.


Novartis signs $150 million deal with Xencor to develop bispecific antibodies

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial

Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …

Latest content